| Clinical and Regulatory | |
|---|---|
| Event Type: | Phase 1/2 Results |
| Timing: | H2 2016 |
| Designation(s): | None |
|
This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
|
|
| Disease and Treatment | |
|---|---|
| Disease: | Neurology |
| Indication: | Alzheimer's Disease |
| Lead Indication?: | No |
| Treatment Name: | ACI-24 |
|
Likelihood of event success varies depending on disease, treatment and lead indication classification.
|
|
| Company Information | |
|---|---|
| Co. Name: | AC Immune |
| Stock Symbol: | ACIU |
| Shares Traded: | NASDAQ |
|
The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
|
|
| Event Status | |
|---|---|
| Event Outcome: | Ongoing |
| Event Discussion: | Forums |
| Event Announcement(s): | https://www.sec.gov/Archives/edgar/data/1651625/000119312516718500/d16439d424b4.htm |
| Partnership: | No |
|
Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
|
|
Detailed Event Description from Company Announcement
QuoteTwo of our other clinical product candidates, ACI-24 and ACI-35, are being developed using our SupraAntigen platform and target AD through active immunization, where the immune system is stimulated to make its own antibodies against pathological proteins:
• ACI-24 is our wholly-owned anti-Abeta vaccine candidate currently in a Phase 1/2a study. We expect to complete this study and announce top line results in the second half of 2016. ACI-24 is also being studied in a Phase 1 clinical study in patients with Down syndrome, a population that is at high risk for AD.